Activated protein C in toxic shock syndrome: a case report.
The mortality from septic shock remains high despite the availability of modern critical care facilities. In recent years, new agents have been tested to reduce morbidity and mortality in patients with severe sepsis. Among them, recombinant human activated protein C (rhAPC) has been reported to significantly reduce mortality and morbidity in patients with severe sepsis and one or more acute organ failures. We describe our experience with this drug in the early reversal of septic shock from toxic shock syndrome.
Department of Critical Care, Wollongong Hospital, Wollongong, New South Wales. rachakondas@iahs.nsw.gov.au
K S
KS
Rachakonda